|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
INCREASE RISK OF INDUCING VENTRICULAR ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
PROLONGATION OF QT INTERVAL MAY BE SERIOUS COMPLICATION
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
HYPOGLYCEMIC EFFECT IS POTENTIATED
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
MAY POTENTIATE THE EFFECTS OF TRICYCLIC ANTIDEPRESSANTS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
PROPAFENONE MAY INCREASE THE PLASMA CONCENTRATION OF THE DRUG
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
MAY POTENTIATE THE ACTION OF DIAZEPAM
|
FLUCONAZOLE INCREASES SERUM PLASMA CONCENTRATION OF THE DRUG
|
RIFAMPICIN MAY ACCELERATES METABOLISM OF THE DRUG & MAY CAUSE DECREASED PLASMA CONCENTRATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|
CO-ADMINISTRATION CAN ENHANCE THE ANTIMUSCARINIC EFFECTS OF THE DRUG LIKE DRYNESS OF MOUTH, PALPITATION ETC
|